Higano CS, et al. Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients. ASCO-GU 2019, abstract 256.
Adjuvant pembrolizumab geeft DFS-voordeel bij RCC
nov 2021 | Uro-oncologie